Airborne, Inc. company makes a dietary supplement that contains herbal extracts, vitamins, electrolytes, amino acids, and antioxidants meant to boost the immune system. The effervescent tablets come in four flavors and a powdered formulation to be added to water. The products are sold nationwide in pharmacies, supermarkets, and mass merchant retailers such as Costco, CVS Caremark, Target, and Wal-Mart. Airborne was established in 1997 by former second-grade teacher Victoria Knight-McDowell. Private equity investors GF Capital Management holds a majority of the company.

Bayer HealthCare Diabetes Care Division is sweet on its customers. Part of Bayer HealthCare's massive worldwide operations, the division markets its parent company's blood glucose monitoring systems, self-care software, and lancing devices to consumers through pharmacies, retail stores, hospitals, and wholesalers. The company manufactures the Ascensia line of blood testing systems (including the Breeze 2 and Contour monitors), which it sells in over 100 countries in Asia, Latin America, North America, and western Europe. Bayer has produced diagnostic products for diabetes since 1941 and developed the first portable blood glucose meter and test strips in 1969.

ZymoGenetics, Inc. company was founded in 1981 and is headquartered in Seattle, Washington. ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The company's product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein, which is in Phase Ib clinical trials for the treatment of viral infections and autoimmune diseases; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases. Its out-licensed product candidates include atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; Augment Bone Graft for orthopedic fracture and other bone defects; rFactor XIII for congenital factor XIII deficiency, cardiac surgery, and cancer related bleeding; Fibroblast growth factor-18 for osteoarthritis; IL-17 receptor C for inflammatory diseases; and IL-20 and IL-22 receptor subunit alpha for psoriasis. The company also offers out-licensed commercial products comprising Novolin and insulin analogs for diabetes; NovoSeven for the treatment of hemophilia; Regranex for wound healing; GEM 21S for periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor for treatment of myocardial infarction. ZymoGenetics has collaboration agreements with Bayer Schering Pharma AG; Bristol-Myers Squibb Company; and Merck Serono S.A.

AVI BioPharma, Inc. was founded in 1980 and is based in Corvallis, Oregon. AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense.

Founded in the early 1900s, LEO Pharma has about two dozen products on the market, many of which treat psoriasis, eczema, and skin infections. The company's other focus areas include developing and manufacturing treatments for blood clot disorders, kidney disease, and support drugs for cancer treatments. Products such as Daivobet, Innohep, and Xamiol are among its best sellers. LEO Pharma has operations in Europe, as well as in the US, Middle East, Africa, and Asia. The company is wholly-owned by the Leo Foundation, which is managed by members of LEO Pharma's executive team.

Stratagene has a strategy for using genes to reach success. The company makes reagents, kits, and other products for gene and protein analysis, gene transfer, protein purification, DNA replication, and other molecular biology applications. It also makes medical diagnostics including allergy testing kits, autoimmune tests that diagnose such disorders as rheumatoid arthritis, and the KOVA urinalysis system. Stratagene sells its products in more than 60 countries; in key markets, the firm uses its own sales force and relies on distributors for other markets. The company is a division of scientific instrument-maker Agilent.

SEQUENOM, Inc. company was founded in 1994 and is headquartered in San Diego, California with additional offices in Queensland, Australia; Beijing, China; and Newton, Massachusetts. Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine, and agricultural and livestock applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations. The company offers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. Sequenom also provides the iPLEX multiplexing assay reagents and chips, which permits multiplexed SNP analysis using a similar amount of reagents and chip surface area. In addition, the company engages in the research, development, and the commercialization of various non-invasive molecular diagnostic tests for prenatal genetic disorders and diseases, oncology, and infectious diseases. It offers its products through direct sales and support personnel to clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies, academic institutions, and government agencies worldwide. Sequenom has a collaboration agreement with the Immune Tolerance Institute to develop an advanced newborn screening test for severe combined immunodeficiency.

ASI Technology Corporation was incorporated in 1931 and is based in Henderson, Nevada. ASI Technology Corporation, together with its subsidiaries, operates as a specialty finance company. The company offers commercial and venture capital loans, as well as provides direct finance leasing services. It also focuses on the development of plasma technology for sterilization and decontamination. The company's patented method uses low voltage to produce high volumes of atmospheric pressure plasma, also known as room temperature or cold plasma.

ReNeuron wants to renew damaged brain cells with stem cell therapy. Founded in 1997 by leading scientists at the London-based Institute of Psychiatry, the company is researching the feasibility of transplanting stem cells into patients with Parkinson's disease, Huntington's disease, type 1 diabetes, stroke, and other neurological disorders. ReNeuron also is studying the possible use of stem cells to treat brain tumors and in non-therapeutic areas with its ReNcell drug development platform. Investors include Merlin Ventures, a leading UK biotechnology investor.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.